{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:29:01Z","timestamp":1792114141086,"version":"4.4.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.chest.2018.08.1058","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T12:20:02Z","timestamp":1536322802000},"page":"1061-1069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":185,"title":["Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis"],"prefix":"10.1016","volume":"154","author":[{"given":"Scott M.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Anstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.chest.2018.08.1058_bib1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"9779","key":"10.1016\/j.chest.2018.08.1058_bib2","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.chest.2018.08.1058_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543784.2010.484018","article-title":"Investigational approaches to therapies for idiopathic pulmonary fibrosis","volume":"19","author":"Gomer","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"issue":"22","key":"10.1016\/j.chest.2018.08.1058_bib4","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2018.08.1058_bib5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2018.08.1058_bib6","doi-asserted-by":"crossref","first-page":"e00027","DOI":"10.1136\/bmjresp-2018-000278","article-title":"Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials","volume":"5","author":"Swigris","year":"2018","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10.1016\/j.chest.2018.08.1058_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak","volume":"14","author":"Tager","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.chest.2018.08.1058_bib8","series-title":"Drug-Induced Liver Disease","first-page":"428","article-title":"Hepatotoxicity, the adverse effects of drugs and other chemicals on the liver","author":"Zimmerman","year":"1999"},{"issue":"6","key":"10.1016\/j.chest.2018.08.1058_bib9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","article-title":"Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study","volume":"3","author":"Jenkins","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"suppl 55","key":"10.1016\/j.chest.2018.08.1058_bib10","first-page":"653","article-title":"Leptin and adiponectin levels in idiopathic pulmonary fibrosis","volume":"38","author":"Malli","year":"2011","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2018.08.1058_bib11","doi-asserted-by":"crossref","first-page":"e0125169","DOI":"10.1371\/journal.pone.0125169","article-title":"Adiponectin attenuates lung fibroblasts activation and pulmonary fibrosis induced by paraquat","volume":"10","author":"Yao","year":"2015","journal-title":"PLoS One"},{"issue":"suppl 61","key":"10.1016\/j.chest.2018.08.1058_bib12","first-page":"PA1038","article-title":"LPA1 antagonists BMS-986020 and BMS-986234 for idiopathic pulmonary fibrosis: preclinical evaluation of hepatobiliary homeostasis","volume":"50","author":"Rosen","year":"2017","journal-title":"Eur Respir J"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369218324115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369218324115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:05:32Z","timestamp":1757923532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369218324115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0012369218324115"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2018.08.1058","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2018.08.1058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}